Real-Time Documentation of the Effect of Onabotulinumtoxin A Detrusor Injection in OAB Patients-Preliminary Results

Toxins (Basel). 2022 Dec 30;15(1):30. doi: 10.3390/toxins15010030.

Abstract

Introduction: Detrusor injection with onabotulinumtoxin A (OnabotA-DI) is an established therapy for overactive bladder (OAB). Little is known about the exact onset and course of the effect in the days after the injection therapy. By using a new type of app-controlled automated diary pod, for the first time, the precise onset of the effect of OnabotA-DI can be documented in real time. Materials and methods: Patients due for OnabotA-DI were asked to document voiding 3 days before and up to 3 weeks after therapy using the Diary Pod app. The detrusor injection was performed with onabotulinumtoxin A (Botox®), 100 units, at 20 sites of the detrusor muscle in a standardized manner. Voiding on the injection day itself was not documented. Results: A total of 17 patients (15 women, 2 men; aged 33−83 (mean 64.6; median 70) years) were included in the study. The handling of the Diary Pod app was user-friendly, and elderly patients did not encounter technical problems. The results of patients with reliably documented micturitions showed a continuous reduction in micturition frequency every day from the first day and significantly from day 5. For 24 h voiding, from 12.83 ± 5.54 in the 3 days before injection, the following mean values were found with significant (p < 0.05) changes after the intervention: 9.17 ± 3.19 on day 5, 8.75 ± 3.69 on day 10, 7.17 ± 2.04 on day 15, and 5.75 ± 0.5 on day 20. These changes were in similar proportions during the daytime and nighttime. Conclusions: Contrary to previous knowledge, the effect of the OnabotA-DI set in from the first postoperative days and was reflected a similar extent in day and night micturition. This study is the first to document the onset of action of OnabotA-DI in real time.

Keywords: botulinum toxin; injections; intramuscular; overactive bladder; urinary bladder; urinary incontinence.

MeSH terms

  • Aged
  • Botulinum Toxins, Type A* / pharmacology
  • Botulinum Toxins, Type A* / therapeutic use
  • Female
  • Humans
  • Injections
  • Male
  • Muscles
  • Neuromuscular Agents* / therapeutic use
  • Urinary Bladder, Overactive* / drug therapy
  • Urination
  • Urodynamics

Substances

  • Botulinum Toxins, Type A
  • Neuromuscular Agents

Grants and funding

This research received no external funding.